Latest papers

A specific pathway inducing autophagic cell death is marked by an IP3R mutation.

Soraphinol C, a new free-radical scavenger from Sorangium cellulosum.

Changes of cytoskeletal proteins in nerve tissues and serum of rats treated with 2,5-hexanedione.

The reversibility of neurofilaments decline induced by 2,5-hexanedione in rat nerve tissues.

Spermatid head retention as a marker of 2,5-hexanedione-induced testicular toxicity in the rat.

A comparison of the apoptotic and cytotoxic effects of hexanedione derivatives on human non-neuronal lines and the neuroblastoma line SH-SY5Y.

A GPCR involved in post aggregation events in Dictyostelium discoideum

Autophagic or necrotic cell death in the absence of caspase and bcl-2 family members.

Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.

[Novel biologically active compounds isolated from unexploited organisms, cellular sime molds].

Expression of Bcl-2, Bax and Caspase-3 in nerve tissues of rats chronically exposed to 2,5-hexanedione.

Time-dependent alteration of cytoskeletal proteins in cerebral cortex of rat during 2,5-hexanedione-induced neuropathy.

New analytical techniques to facilitate preformulation screening in propellant systems.

Dictyostelium differentiation-inducing factor-1 induces glucose transporter 1 translocation and promotes glucose uptake in mammalian cells.

Effect of physical exertion on the biological monitoring of exposure to various solvents following exposure by inhalation in human volunteers: II. n-Hexane.

[Resveratrol helps restore spermatogenesis after testis injury induced by 2,5-hexanedione].

Two-dimensional capillary electrophoresis using tangentially connected capillaries.

An activity, stability and selectivity comparison of propioin synthesis by thiamine diphosphate-dependent enzymes in a solid/gas bioreactor.

The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.

Phase I trial of imexon in patients with advanced malignancy.